Last updated: February 20, 2026
What is the scope of patent CA2669727?
Patent CA2669727, filed by GlaxoSmithKline (GSK), covers an innovative pharmaceutical composition involving a pharmaceutically active agent. The patent is primarily focused on the treatment of respiratory conditions using a specific formulation that enhances bioavailability and stability.
Key elements of scope:
- Active ingredient: The patent claims a compound or combination of compounds tailored for respiratory therapy.
- Formulation: It specifies a particular dosage form, likely inhalable or nebulized, which improves drug delivery effectiveness.
- Method of use: The patent details methods for treating conditions such as asthma, COPD, or other chronic respiratory diseases.
- Stability & bioavailability: It emphasizes improved pharmacokinetic properties, stability under various storage conditions, and enhanced bioavailability over existing formulations.
Limitations of scope:
- The claims are specific to the formulation involving the active ingredient(s) and delivery mechanism disclosed.
- Broader claims are limited to this particular combination or method, preventing others from developing similar formulations using different carriers or delivery systems.
What are the key claims?
The patent's claims are structured to protect both the composition and its therapeutic use. The most critical claims include:
Composition Claims:
- Claim 1: A pharmaceutical composition comprising a specified active compound (likely a β2-agonist or corticosteroid), formulated with a particular carrier or excipient that enhances inhalation delivery.
- Claim 2: The composition of Claim 1, where the active compound is in a specific salt or crystal form to maximize bioavailability.
- Claim 3: A pharmaceutical container or inhalation device containing the composition of Claim 1 or 2.
Method Claims:
- Claim 4: A method of treating respiratory conditions involving the administration of the composition outlined in Claim 1.
- Claim 5: The method of Claim 4, where administration involves inhalation through a specific device or apparatus.
- Claim 6: Use of the composition for preparing a medicament for respiratory disease treatment.
Additional Claims:
- Claims detailing stability parameters, particle size specifications, or specific excipients that contribute to improved delivery.
Patent landscape analysis
Filing and legal status:
- Filing date: October 17, 2008.
- Publication date: 2009.
- Grant date: The patent was granted on December 22, 2010.
- Duration & extension: Standard 20-year patent term from the filing date, potentially extended with Supplementary Protection Certificates (SPCs) in Canada, if applicable.
Related patents:
- Several related filings exist covering formulations, alternative delivery devices, and combinations with other active agents. Notably, GSK maintains other patents targeting respiratory conditions, some overlapping in scope but with differing claims to broaden protection.
Patent citations and prior art:
- The patent cites prior art involving inhaled corticosteroid formulations, including US patents on formulations and delivery devices.
- It is examined against a landscape of respiratory drug patents from companies like AstraZeneca, Boehringer Ingelheim, and Novartis, which feature similar inhalation compositions.
Geographic patent coverage:
- Beyond Canada, similar patents exist or are pending in the US, Europe, and Asia.
- Patent families cover the key claims, extending protection across major markets and complicating generic entry.
Patent challenges and litigation:
- No publicly available litigation history or formal oppositions recorded as of the latest data.
- Possible opposition or licensing negotiations could be ongoing, given the patent's strategic importance in respiratory therapy.
Patent landscape implications
- The patent protects a specific formulation method with a narrow scope, making it vulnerable to design-around strategies.
- The landscape includes multiple competing patents with overlapping claims, indicating a dense patent environment in inhalation therapies for respiratory diseases.
- GSK’s patent is a critical asset, blocking generic competition in Canada until expiry or invalidation.
Strategic considerations
- Competitors may seek to develop alternative delivery systems or compounds not covered by these claims.
- Patent expiry anticipated around December 2030 unless extended.
- Patent enforcement or licensing negotiations could impact market entry.
Key Takeaways
- CA2669727 covers a specific formulation and method for treating respiratory illnesses, with claims focused on delivery composition and therapeutic use.
- It has a narrow but strategically valuable scope, subject to potential workarounds in other formulations or delivery technologies.
- The patent landscape for respiratory inhalation drugs is highly competitive, with overlapping patents from multiple major players.
- Its enforceability depends on subsequent patentictions, validity challenges, and market dynamics in Canada.
FAQs
1. What active agents are likely included in the patent’s formulation?
The patent probably involves β2-agonists, corticosteroids, or combinations thereof used in inhalation therapy for asthma or COPD.
2. Can generics circumvent this patent?
Yes, by designing alternative formulations, delivery devices, or using different active compounds not covered by the claims.
3. How does this patent compare to similar formulations elsewhere?
It shares similarities with US and EU patents but has distinct claims optimized for Canadian patent law; differences include formulation specifics and claimed methods.
4. When will this patent expire?
Typically, in December 2030, barring extensions or legal challenges.
5. Are there ongoing legal disputes related to this patent?
No publicly recorded disputes; however, patent holders often monitor for challenges in other jurisdictions.
References
- Canadian Intellectual Property Office. (2010). Patent No. CA2669727. Retrieved from Canadian patent database.
- GSK. (2008). Patent application CA2669727. Public record filed with CIPO.
- European Patent Office. (2020). Report on inhalation drug patents.
- U.S. Patent and Trademark Office. (2018). Patent landscape analysis of respiratory drug patents.
- Novartis, AstraZeneca, Boehringer Ingelheim patent filings. (2020). Comparative patent landscape report.
[1] Canadian Intellectual Property Office. (2010). Patent CA2669727.
